Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants
- PMID: 21833166
- PMCID: PMC3153001
- DOI: 10.3389/fphar.2010.00121
Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants
Abstract
Polymorphic expression of CYP2D6 contributes to the wide range of activity observed for this clinically important drug metabolizing enzyme. In this report we describe novel CYP2D7/2D6 hybrid genes encoding non-functional and functional CYP2D6 protein and a CYP2D7 variant that mimics a CYP2D7/2D6 hybrid gene. Five-kilobyte-long PCR products encompassing the novel genes were entirely sequenced. A quantitative assay probing in different gene regions was employed to determine CYP2D6 and 2D7 copy number variations and the relative position of the hybrid genes within the locus was assessed by long-range PCR. In addition to the previously known CYP2D6*13 and *66 hybrids, we describe three novel non-functional CYP2D7-2D6 hybrids with gene switching in exon 2 (CYP2D6*79), intron 2 (CYP2D6*80), and intron 5 (CYP2D6*67). A CYP2D7-specific T-ins in exon 1 causes a detrimental frame shift. One subject revealed a CYP2D7 conversion in the 5'-flanking region of a CYP2D6*35 allele, was otherwise unaffected (designated CYP2D6*35B). Finally, three DNAs revealed a CYP2D7 gene with a CYP2D6-like region downstream of exon 9 (designated CYP2D7[REP6]). Quantitative copy number determination, sequence analyses, and long-range PCR mapping were in agreement and excluded the presence of additional gene units. Undetected hybrid genes may cause over-estimation of CYP2D6 activity (CYP2D6*1/*1 vs *1/hybrid, etc), but may also cause results that may interfere with the genotype determination. Detection of hybrid events, "single" and tandem, will contribute to more accurate phenotype prediction from genotype data.
Keywords: CYP2D6; CYP2D6 poor metabolizer; CYP2D6*35B; CYP2D6*67; CYP2D6*79; CYP2D6*80; hybrid genes.
Figures





Similar articles
-
CYP2D7-2D6 hybrid tandems: identification of novel CYP2D6 duplication arrangements and implications for phenotype prediction.Pharmacogenomics. 2010 Jan;11(1):43-53. doi: 10.2217/pgs.09.133. Pharmacogenomics. 2010. PMID: 20017671 Free PMC article.
-
Frequency of undetected CYP2D6 hybrid genes in clinical samples: impact on phenotype prediction.Drug Metab Dispos. 2012 Jan;40(1):111-9. doi: 10.1124/dmd.111.040832. Epub 2011 Oct 17. Drug Metab Dispos. 2012. PMID: 22004686 Free PMC article.
-
CYP2D7 Sequence Variation Interferes with TaqMan CYP2D6 (*) 15 and (*) 35 Genotyping.Front Pharmacol. 2016 Jan 12;6:312. doi: 10.3389/fphar.2015.00312. eCollection 2015. Front Pharmacol. 2016. PMID: 26793106 Free PMC article.
-
Complexities of CYP2D6 gene analysis and interpretation.Int Rev Psychiatry. 2013 Oct;25(5):534-53. doi: 10.3109/09540261.2013.825581. Int Rev Psychiatry. 2013. PMID: 24151800 Review.
-
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.Drug Metab Rev. 2007;39(1):45-60. doi: 10.1080/03602530600952206. Drug Metab Rev. 2007. PMID: 17364880 Review.
Cited by
-
CYP2D6 Genetic Variation and Its Implication for Vivax Malaria Treatment in Madagascar.Front Pharmacol. 2021 Apr 20;12:654054. doi: 10.3389/fphar.2021.654054. eCollection 2021. Front Pharmacol. 2021. PMID: 33959023 Free PMC article.
-
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence.Clin Transl Sci. 2022 Oct;15(10):2514-2527. doi: 10.1111/cts.13380. Epub 2022 Aug 23. Clin Transl Sci. 2022. PMID: 35997001 Free PMC article.
-
PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting.Clin Pharmacol Ther. 2023 Dec;114(6):1220-1237. doi: 10.1002/cpt.3044. Epub 2023 Sep 28. Clin Pharmacol Ther. 2023. PMID: 37669183 Free PMC article. Review.
-
Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.J Child Adolesc Psychopharmacol. 2024 Dec;34(10):458-469. doi: 10.1089/cap.2024.0069. Epub 2024 Oct 10. J Child Adolesc Psychopharmacol. 2024. PMID: 39387268
-
The Impact of the CYP2D6 "Enhancer" Single Nucleotide Polymorphism on CYP2D6 Activity.Clin Pharmacol Ther. 2022 Mar;111(3):646-654. doi: 10.1002/cpt.2469. Epub 2021 Nov 30. Clin Pharmacol Ther. 2022. PMID: 34716917 Free PMC article.
References
-
- Daly A. K., Fairbrother K. S., Andreassen O. A., London S. J., Idle J. R., Steen V. M. (1996). Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype. Pharmacogenetics 6, 319–32810.1097/00008571-199608000-00005 - DOI - PubMed
-
- de Leon J., Susce M. T., Johnson M., Hardin M., Maw L., Shao A., Allen A. C., Chiafari F. A., Hillman G., Nikoloff D. M. (2009). DNA microarray technology in the clinical environment: the AmpliChip CYP450 test for CYP2D6 and CYP2C19 genotyping. CNS Spectrums 14, 19–34 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical